Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma

Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma

Chimeric antigen receptor T (CAR-T) cell therapy has proven to be very effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). However, infections—related either due to lymphodepletion or the CAR-T cell therapy itself—can result in severe and...

Full description

Bibliographic Details
Main Authors: Felix Korell, Maria-Luisa Schubert, Tim Sauer, Anita Schmitt, Patrick Derigs, Tim Frederik Weber, Paul Schnitzler, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
CAR-T cell
infection
lymphodepletion
cytokine release syndrome
Online Access:https://www.mdpi.com/2072-6694/13/7/1684

Internet

https://www.mdpi.com/2072-6694/13/7/1684

Similar Items